Figure 1 — Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer

Research Paper|Volume 8, Issue 12|pp. 3520–3534

Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer

Back to articleFigure 1(1 of 11)

100%

Figure 1.The content of sFlt1 in supernatant increased significantly in MSCs-sFlt1 group as compared with day-matched MSCs-adv group or MSCs group. Data from 3 independent experiments are shown. *P<0.05 versus MSC-sFlt1 group.